Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report issued on Thursday morning,Benzinga reports. Chardan Capital currently has a $14.00 price objective on the stock.

A number of other research analysts have also recently weighed in on COYA. D. Boral Capital restated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a research report on Monday, November 24th. Lake Street Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Coya Therapeutics in a report on Wednesday, November 5th. Finally, Wall Street Zen upgraded Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Trading Down 5.3%

COYA stock opened at $4.85 on Thursday. The business’s fifty day moving average price is $5.81 and its 200 day moving average price is $6.04. Coya Therapeutics has a 12-month low of $4.65 and a 12-month high of $8.29. The company has a market capitalization of $101.48 million, a PE ratio of -4.37 and a beta of 0.25.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.12). The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $3.70 million. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. Research analysts predict that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Trading of Coya Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new stake in Coya Therapeutics during the 3rd quarter worth about $28,000. Lantern Wealth Advisors LLC purchased a new position in shares of Coya Therapeutics in the 3rd quarter valued at about $66,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Coya Therapeutics during the 2nd quarter worth about $119,000. Prosperity Wealth Management Inc. raised its position in shares of Coya Therapeutics by 16.4% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after acquiring an additional 3,350 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after purchasing an additional 13,176 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.